SOURCE: Crucell N.V.

April 26, 2007 08:07 ET

Crucell to Release Q1 2007 Earnings on Wednesday, May 9, 2007

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- April 26, 2007 --

Leiden, The Netherlands, April 26, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it will release its financial results for the first quarter of 2007 on Wednesday, May 9th, 2007 at 08:00 Central European Time (CET) (02:00 US Eastern Daylight Time).

At 14:00 CET, Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement:

1-888 495 6450 for the US
0800 358 3476 for the UK; and
0800 265 8593 for the Netherlands.
Following a presentation of the results you will be able to ask questions during a question and answer session.

The live audio webcast can be accessed via the homepage of Crucell's website at, and will be archived and available for replay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                      For Crucell in the US:
Leonard Kruimer                   Redington, Inc.
Chief Financial Officer           Thomas Redington
Tel. +31-(0)71-524 8722           Tel. +1 212-926-1733

Barbara Mulder
Director Corporate Communications
Tel: 31-(0) 71 524 8718

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information